Press release
Catalyst Biosciences to Participate in Two Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that members of its executive
About this update from Gyre Therapeutics, Inc.
[{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that members of its executive management team will participate in fireside chats at the two investor conferences in June: Raymond James Human Health Innovation Conference and the JMP Securities Life Sciences Conference. JMP Securities Life Sciences Conference Date:Wednesday, June 16, 2021Time:1:30 PM Eastern TimeWebcast:JMP Webcast Raymond James Human Health Innovation Conference Date:Wednesday, June 23, 2021Time:11:20 AM Eastern TimeWebcast:RJ Webcast An archived webcast of the presentations will be available for 90 days on the Events and Presentations section of the Company’s website. About Catalyst Biosciences, the Protease Medicines companyCatalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems. Our protease engineering platform has generated two late-stage clinical programs, including MarzAA, a subcutaneously (SQ) administered next-generation engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders. Our complement pipeline includes a preclinical C3-degrader program licensed to Biogen for dry age-related macular degeneration, an improved complement factor I protease for SQ replacement therapy in patients with CFI deficiency and C4b-degraders designed to target disorders of the classical complement pathway as well as other complement programs in development. Forward-Looking StatementsThis press release contains forward-looking statements that involve substantial risks and uncertainties. Forward-looking statements include statements about, the potential benefits of products based on Catalyst’s engineered protease platform, and the Company’s collaboration with Biogen for the development and commercialization of a pre-clinical C3-degrader program dry age-related macular degeneration. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially, including, but not limited to, the risk that trials and studies may be delayed as a result of COVID-19, competitiv...